Harrow, Inc.
HROW- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001360214
In the last 90 days, Harrow, Inc. insiders filed 0 open-market purchases and 1 sale; 223 institutions reported holding it in 13F filings for Q2 2026, worth $912.6M in total; no superinvestor holds it.
Holders of 5% or more of HROW
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Harrow, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Baum Mark L | 13D/A | 10.69%4.06M shares | – | Apr 7, 20251 filing | Apr 7, 2025 | SEC |
| Opaleye Management Inc. | 13G/A | 7.61%2.83M shares | – | May 11, 20261 filing | May 11, 2026 | SEC |
| Kaufman Daniel Louis | 13G | 5.04%1.88M shares | New | Mar 11, 20261 filing | Mar 11, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
4 Schedule 13D and 13G filings on Harrow, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| May 11, 20264:20 PM ET | Opaleye Management Inc.and 2 others | 13G/A | 7.61%2.83M shares | – | Mar 31, 2026 | SEC |
| Mar 27, 20269:34 AM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | –Below 5% | Mar 13, 2026 | SEC |
| Mar 11, 20262:50 PM ET | Kaufman Daniel Louis | 13G | 5.04%1.88M shares | New | Mar 10, 2026 | SEC |
| Apr 7, 20259:54 PM ET | Baum Mark L | 13D/A | 10.69%4.06M shares | – | Apr 3, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Harrow, Inc. shares.
No Form 144 notices for Harrow, Inc. are on file.